SAN CARLOS, Calif.--September 23, 2026--Glycomine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GLM101 for the treatment of phosphomannomutase 2 congenital...
Arthur Klausner to speak at Biotech & Life Science Global Venture Congress 2006 in New York City
News | 09. 14. 2006
